A Double-blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate Safety and Efficacy of AMG 145 in Combination With Statin Therapy in Diabetic Subjects With Hyperlipidemia or Mixed Dyslipidemia
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 11 Sep 2017
At a glance
- Drugs Evolocumab (Primary) ; Atorvastatin
- Indications Dyslipidaemias; Hyperlipidaemia
- Focus Registrational; Therapeutic Use
- Sponsors Amgen
- 07 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 27 Mar 2017 Planned End Date changed from 1 Jul 2017 to 4 Dec 2017.
- 27 Mar 2017 Planned primary completion date changed from 1 Jul 2017 to 4 Dec 2017.